Introduction
============

Ovarian cancer is ranked as the 8^th^ most common cancer among women worldwide, with an age-standardized incidence rate of 6.6. Epithelial ovarian cancer (EOC) accounts for over 90% of all ovarian cancers \[[@B1]\]. Since there is no effective screening test for EOC, over 75% of the patients in the sample were diagnosed with cancer at an advanced stage, resulting in poor outcomes. The standard treatment consists of surgery followed by platinum-based chemotherapy, usually administered in 6 cycles of carboplatin and paclitaxel (PT) with or without bevacizumab. However, the median progression-free interval, especially in the advanced stages of cancer, was about 18 months, with approximately 80% of patients having a recurrence within 1--2 years \[[@B2]\].

In addition, patients with tumor progression over 6 months after completing treatment with platinum-based chemotherapy could be benefit from retreatment with the platinum-based regimen again and were categorized as platinum-sensitive patients. In contrast to patients whose tumor progression during or under 6 months after completing treatment showed very poor prognoses and were categorized as platinum-resistant patients due to no benefit from platinum-based chemotherapy \[[@B3]\]. Considering these findings, it is imperative to discover potential predictive factors that identify patients who are resistant to platinum-based treatment and at a high risk of early progression. If identified earlier, platinum-resistant EOC patients could benefit from aggressive therapeutic schedules in the first-line treatment, such as extensive surgical debulking procedure, use of dose-dense chemotherapy, or addition of a targeted therapy (e.g., bevacizumab).

A recent molecular cancer study suggested that an increase in the parameters of inflammatory markers, such as neutrophils and platelets, could facilitate tumor initiation, tumor progression, induction of angiogenesis, and promote metastatic spreading by inhibiting the natural killer functions of the body \[[@B4]\]. Thus, the elevated neutrophil-to-lymphocyte ratios (NLRs) and platelet-to-lymphocyte ratios (PLRs) in many solid tumors can be associated with worse prognoses \[[@B5]\]. In addition, other clinical manifestations such as the presence of malignant ascites, a suboptimal residual tumor, a high cancer antigen 125 (CA125) reading and a high-grade tumor can also be related to poorer outcomes \[[@B5]-[@B7]\]. However, studies to predict the factors involved in platinum-based chemotherapeutic responses are still limited. This study was conducted as a retrospective review to identify the potential clinical and blood inflammatory parameters that could be used to predict platinum status and survival outcomes in patients with EOC.

Materials and methods
=====================

1. Patient selection {#sec1}
--------------------

This retrospective study was conducted following the approval by the Research Ethics Committee at Chiang Mai University Hospital. The medical records of patients with EOC, fallopian tube cancer and primary peritoneal adenocarcinoma who were initially treated through either primary surgery or neoadjuvant chemotherapy before surgery at the Chiang Mai University Hospital, between January 2007 and December 2017, were retrospective reviewed. Patients with missing data were excluded. Finally, 306 patients who met the inclusion criteria were recruited into the study. The following clinical and pathological data were collected: age, body mass index, parity, menopausal status, the presence of ascites, primary treatment, International Federation of Gynecology and Obstetrics (FIGO) staging, residual disease, estimated blood loss during surgery, operative time, histology, and tumor grade. All patients enrolled in the study underwent comprehensive surgical staging or tumor debulking as clinically indicated. Optimal debulking was defined as a procedure that left a maximum residual tumor of less than 1 cm. The chemotherapy regimens consisted of carboplatin area under the curve (AUC)=5 plus paclitaxel 175 mg/m^2^ (PT regimen) or single carboplatin AUC 5--6. All regimens were given every 3 weeks for a total of 6 cycles. If disease progression or severe toxicity occurred, chemotherapy was discontinued. In addition, some patients continued on a chemotherapy regimen beyond 6 cycles if deemed necessary by their physicians. Neoadjuvant chemotherapy was administered when debulking surgery was not suitable for the patient.

Blood tests for ovarian cancer antigen (CA125) and hematologic markers were collected within 3 weeks prior to initial treatment. NLR and PLR were calculated from complete blood cell count using the absolute neutrophil count divided by the absolute lymphocyte count and the absolute platelet count divided by the absolute lymphocyte count, respectively.

After treatment was completed, the patients\' response to therapy was evaluated using radiologic evaluation and/or CA125 measurement. Follow up included a physical examination and a CA125 blood test every 3 months in the 1^st^ year, every 4 months in the 2^nd^ year, every 6 months in the 3^rd^ to 5^th^ years, and subsequently annually. The diagnosis of progression was determined according to the Response Evaluation Criteria in Solid Tumors or tumor markers.

Patients were divided into 2 groups according to the time to progression after chemotherapy was discontinued. The first group was defined as the platinum-resistant group as patients developed tumor progression during or within 6 months of completion of chemotherapy. The second group was defined as the platinum-sensitive group as tumor progression occurred at 6 months or longer after completion of treatment.

Overall survival was defined as the time from treatment initiation to the last follow up or death.

2. Statistical analysis {#sec2}
-----------------------

Statistical analysis was performed using the IBM SPSS Statistics for Windows program (version 22; IBM Corp., Armonk, NY, USA). Chi-square or Fisher\'s exact test were used for the comparative analysis of the factors between the platinum-resistant and -sensitive groups and to calculate odds ratios (ORs) for the categorical variables. They were also used for comparative clinical variables between both cut-point NLR and PLR. A receiver operating characteristic (ROC) curve was used to assess the discriminative role of the NLR, PLR, and CA125 levels, and the best cutoff value for each item was determined to further predict the platinum status. Binary logistic regression analysis with a backward likelihood ratio method was used to identify the potential independent predictive factors for platinum resistance. The cumulative survival curve was estimated using the Kaplan-Meier method. A comparison between survival curves for each factor was carried out using the log rank test for the analysis of equality of survival distribution. Cox proportional hazard models were applied to explore predictors of survival outcomes through univariate and multivariate analyses. A *P*-value of \<0.05 was considered statistically significant.

Results
=======

The patient characteristics are noted in [Table 1](#T1){ref-type="table"}. Over 80% of patients were diagnosed with EOC and half of them had advanced-stage cancer. Neoadjuvant chemotherapy was administered in 24.5% of the patients, with the primary regimen being carboplatin plus paclitaxel (PT). Most patients received 3 cycles. The surgery achieved no residual disease and optimal status in 49.3% and 17.6% of cases, respectively. Approximately 41.2% of the patients\' histology revealed serous cystadenocarcinoma. Over 90% of the studied patients received adjuvant chemotherapy with PT regimen, whereas the remaining patients received single carboplatin. One patient did not receive adjuvant chemotherapy because she received 6 cycles of PT regimen in the neoadjuvant chemotherapy setting; the final histology from surgery revealed no malignancy. Majority of the studied patients were given 6 cycles of adjuvant chemotherapy with maximum number 10 cycles in 1 patient who received 4 cycles of PT regimen before developing transaminitis. This patient\'s chemotherapy regimen was changed to carboplatin for a further 6 cycles.

###### Patient characteristics (n=306)

![](ogs-63-55-i001)

  Characteristics                                                 Value                                                                     
  --------------------------------------------------------------- ------------------------------------------- ----------------------------- ------------
  Mean age (years)                                                54.14±9.72                                                                
  Mean BMI (kg/m^2^)                                              22.95±3.78                                                                
  Median CA125 (range: 8.5--40,340)                               373.5                                                                     
  Hematologic parameters (range)                                                                                                            
                                                                  Hemoglobin (7.6--15.0; gm%)                 11.46 (11.5)                  
                                                                  WBC (3,860--30,500; cu.mm.)                 8,848 (7,935)                 
                                                                  ANC (1,599.6--26,901.0; cu.mm.)             6,362.7 (5,341.0)             
                                                                  Platelet (79,000--909,000; cu.mm.)          369,685 (335,000)             
                                                                  NLR (0.64--30.75)                           4.3 (3.4)                     
                                                                  PLR (42.54--1,078.90)                       245.5 (209.9)                 
  Mean estimated blood loss (median: 400, range: 50--5,000; mL)   660±674.59                                                                
  Mean operative time (minutes)                                   174.93±59.83                                                              
  Menopause                                                       196 (64.1)                                                                
  Nulliparity                                                     105 (34.3)                                                                
  Epithelial ovarian cancer                                       249 (81.4)                                                                
  Fallopian tube cancer                                           35 (11.4)                                                                 
  Primary peritoneal cancer                                       22 (7.2)                                                                  
  FIGO stage                                                                                                                                
                                                                  I                                           92 (30.1)                     
                                                                  II                                          22 (7.19)                     
                                                                  III                                         129 (42.2)                    
                                                                  IV                                          18 (5.9)                      
  Surgical outcome                                                                                                                          
                                                                  No residual tumor                           151 (49.3)                    
                                                                  Optimal status (residual tumor \>1 cm)      54 (17.6)                     
                                                                  Suboptimal status (residual tumor \>1 cm)   101 (33.0)                    
  Histology                                                                                                                                 
                                                                  Serous                                      126 (41.2)                    
                                                                  Mucinous                                    19 (6.2)                      
                                                                  Endometrioid                                38 (12.4)                     
                                                                  Clear cell                                  80 (26.1)                     
                                                                  Mixed                                       33 (10.8)                     
                                                                  Adenocarcinoma                              9 (2.9)                       
                                                                  Transitional cell carcinoma                 1 (0.3)                       
  Primary treatment                                                                                                                         
                                                                  Neoadjuvant chemotherapy                    75 (24.5)                     
                                                                                                              Carboplatin plus paclitaxel   69 (22.5)
                                                                                                              Carboplatin                   6 (2.0)
                                                                  Cycle of neoadjuvant chemotherapy                                         
                                                                                                              1                             7
                                                                                                              2                             9
                                                                                                              3                             39
                                                                                                              4                             10
                                                                                                              5                             2
                                                                                                              6                             8
                                                                  Upfront surgery                             231 (75.5)                    
                                                                  Adjuvant chemotherapy                       305                           
                                                                                                              Carboplatin plus paclitaxel   283 (92.8)
                                                                                                              Single carboplatin            22 (7.2)
                                                                  No. of adjuvant chemotherapy                                              
                                                                                                              1                             3
                                                                                                              2                             9
                                                                                                              3                             43
                                                                                                              4                             18
                                                                                                              5                             9
                                                                                                              6                             213
                                                                                                              7                             4
                                                                                                              8                             2
                                                                                                              9                             3
                                                                                                              10                            1
  Platinum status                                                                                                                           
                                                                  Resistant                                   118 (38.6)                    
                                                                  Sensitive                                   188 (61.4)                    
  Final status                                                                                                                              
                                                                  Death                                       146 (47.7)                    

Values are presented as mean±standard deviation, number (%) or mean (median).

BMI, body mass index; CA125, cancer antigen 125; WBC, white blood cell; ANC, absolute neutrophil count; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; FIGO, International Federation of Gynecology and Obstetrics.

Platinum resistance was found in approximately 40% of the patients. To identify the potential predictive factors of platinum resistance, ROC and the AUC for the optimum cutoff points of NLR, PLR, and CA125 were used, and the results showed the most effective cutoff point were 3.38 for NLR, 210 for PLR, and 365 IU/L for CA125 ([Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

![ROC and AUC for hematologic parameters to predict platinum status. NLR, neutrophil-to-lymphocyte ratio; PLR, platelettolymphocyte ratio; CI, confidence interval; ROC, receiver operating characteristic; AUC, area under the curve.](ogs-63-55-g001){#F1}

![ROC and AUC for CA125 level to predict platinum status. CA125, cancer antigen 125; CI, confidence interval; ROC, receiver operating characteristic; AUC, area under the curve.](ogs-63-55-g002){#F2}

The possible risk factors for predicting platinum resistance were categorized into 2 groups for comparison in the univariate analysis, and the significant factors were further evaluated in the multivariate analysis as noted in [Table 2](#T2){ref-type="table"}. The results showed the risk factor NLR to be \>3.38, PLR to be \>210, and CA125 levels to be [\>]{.ul}365 IU/L. Advanced stage, suboptimal disease, serous type and the presence of ascites were significant potential predictive factors for platinum resistance. However, only an NLR \>3.38 and advanced stage were independent potential predictive factors for platinum resistance with the adjusted ORs of 1.880 and 3.333, respectively.

###### Factors to predict platinum status

![](ogs-63-55-i002)

  Factors                No. of patients divided by platinum status   Total       Univariate analysis^a)^   Multivariate analysis^b)^                                                           
  ---------------------- -------------------------------------------- ----------- ------------------------- --------------------------- ---------------------- --------- ---------------------- ---------
  NLR                                                                                                                                                                                           
                         \>3.38                                       74 (24.2)   78 (25.5)                 152                         2.372 (1.478--3.805)   \<0.001   1.880 (1.144--3.090)   0.013
                         ≤3.38                                        44 (14.4)   110 (35.9)                154                                                                                 
  PLR                                                                                                                                                                                           
                         \>210                                        73 (23.9)   80 (26.1)                 153                         2.190 (1.368--3.507)   0.001     1.368 (0.792--2.365)   0.261
                         ≤210                                         45 (14.7)   108 (35.3)                153                                                                                 
  CA125 level (IU/L)                                                                                                                                                                            
                         ≥365                                         69 (22.5)   81 (26.5)                 150                         1.860 (1.167--2.965)   0.009     0.992 (0.553--1.780)   0.978
                         \< 365                                       49 (16.0)   107 (35.0)                156                                                                                 
  Parity                                                                                                                                                                                        
                         Nulliparity                                  39 (12.7)   66 (21.6)                 105                         0.913 (0.561--1.485)   0.712     1.153 (0.676--1.968)   0.602
                         Multiparity                                  79 (25.8)   122 (39.9)                201                                                                                 
  Stage                                                                                                                                                                                         
                         Advanced (III & IV)                          88 (28.8)   82 (26.8)                 170                         3.792 (2.289--6.282)   \<0.001   3.333 (1.989--5.585)   \<0.001
                         Early (I & II)                               30 (9.8)    106 (34.6)                136                                                                                 
  Postoperative status                                                                                                                                                                          
                         Suboptimal                                   48 (15.7)   53 (17.3)                 101                         1.747 (1.075--2.839)   0.024     1.031 (0.590--1.802)   0.915
                         Optimal                                      70 (22.9)   135 (44.1)                205                                                                                 
  Histology                                                                                                                                                                                     
                         Serous                                       57 (18.6)   69 (22.5)                 126                         1.612 (1.010--2.571)   0.045     0.816 (0.461--1.445)   0.485
                         Non-serous                                   61(19.9)    119 (38.9)                180                                                                                 
  Tumor grade                                                                                                                                                                                   
                         High grade                                   99 (32.4)   145 (47.4)                244                         1.545 (0.850--2.808)   0.152     1.254 (0.659--2.386)   0.490
                         Low grade                                    19 (6.2)    43 (14.1)                 62                                                                                  
  Ascites                                                                                                                                                                                       
                         Presence                                     55 (18.0)   61 (20.0)                 116                         1.774 (1.106--2.846)   0.017     0.883 (0.484--1.613)   0.687
                         Absence                                      63 (20.7)   126 (41.3)                189                                                                                 

OR, odd ratio; CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CA125, cancer antigen 125.

^a)^Chi-square test; ^b)^Binary regression analysis (backward ratio statistic).

Regarding prognostic factors related to survival outcomes, an NLR \>3.38, a PLR \>210, a CA125 [\>]{.ul}365 IU/L, advanced stage, suboptimal diseases, serous histology, tumor grade and the presence of ascites showed a poor 5-year overall survival rate in the univariate analysis. However, only a PLR \> 210 and an advanced stage diagnosis were independent potential prognostic factors for survival, with the respective adjusted hazard ratios (HRs) of 1.578 and 3.994. These details are presented in [Table 3](#T3){ref-type="table"}.

###### Factors related to 5-year overall survival rate
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  Factors                Total                 5-year overall survival rate (%)   Univariate analysis   Cox-Regression analysis^a)^                                    
  ---------------------- --------------------- ---------------------------------- --------------------- ----------------------------- --------- ---------------------- ---------
  NLR                                                                                                                                                                  
                         \>3.38                152                                34.1                  1.987 (1.421--2.778)          \<0.001   1.398 (0.958--2.040)   0.083
                         ≤3.38                 154                                61.2                                                                                 
  PLR                                                                                                                                                                  
                         \>210                 153                                33.9                  2.243 (1.599--3.146)          \<0.001   1.578 (1.045--2.381)   0.030
                         ≤210                  153                                61.0                                                                                 
  CA125 level (IU/L)                                                                                                                                                   
                         ≥365                  150                                36.6                  1.768 (1.270--2.462)          0.001     1.225 (0.826--1.818)   0.314
                         \< 365                156                                58.4                                                                                 
  Parity                                                                                                                                                               
                         Nulliparity           105                                55.9                  1.220 (0.860--1.730)          0.210     0.960 (0.672--1.370)   0.821
                         Multiparity           201                                43.6                                                                                 
  Stage                                                                                                                                                                
                         Advanced (III & IV)   170                                26.2                  4.450 (2.996--6.611)          \<0.001   3.994 (2.498--6.384)   \<0.001
                         Early (I & II)        136                                76.4                                                                                 
  Postoperative status                                                                                                                                                 
                         Suboptimal            101                                32.7                  1.775 (1.271--2.477)          0.001     1.283 (0.895--1.838)   0.175
                         Optimal               205                                54.8                                                                                 
  Histology                                                                                                                                                            
                         Serous                126                                31.1                  1.791 (1.289--2.490)          0.001     1.061 (0.722--1.560)   0.761
                         Non-serous            180                                57.8                                                                                 
  Tumor grade                                                                                                                                                          
                         High grade            244                                43.1                  2.005 (1.249--3.217)          0.004     1.366 (0.837--2.230)   0.212
                         Low grade             62                                 66.1                                                                                 
  Ascites                                                                                                                                                              
                         Presence              116                                29.8                  2.181 (1.574--3.024)          \<0.001   1.233 (0.834--1.825)   0.294
                         Absence               189                                58.9                                                                                 

HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CA125, cancer antigen 125.

^a)^Cox proportional hazard model; ^b)^ Log rank test.

Furthermore, both a high NLR (\>3.38) and PLR (\>210) were found to be significant in patients with a high CA125 reading ([\>]{.ul}365 IU/L), advanced stage, suboptimal residual tumors and presence of ascites, as noted in [Table 4](#T4){ref-type="table"}.

###### Clinical variable divided by neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR)
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  Variables                   NLR          PLR                                              
  --------------------------- ------------ ------------ --------- ------------ ------------ ---------
  CA125 \<365 IU/L            99 (32.4)    57 (18.6)    \<0.001   100 (31.7)   56 (18.3)    \<0.001
  CA125 ≥365 IU/L             55 (18.0)    95 (31.0)              53 (17.3)    97 (31.7)    
  Early stage (I & II)        87 (28.4)    49 (16.0)    \<0.001   88 (28.8)    48 (15.7)    \<0.001
  Advance stage (III & IV)    67 (21.9)    103 (33.7)             65 (21.2)    105 (34.3)   
  Optimal residual tumor      112 (36.6)   93 (30.4)    0.032     112 (36.6)   93 (30.4)    0.021
  Suboptimal residual tumor   42 (13.7)    59 (19.3)              41 (13.4)    60 (19.6)    
  Non-serous type             101 (33.0)   79 (25.8)    0.016     94 (30.7)    86 (28.1)    0.353
  Serous type                 53 (17.3)    73 (23.9)              59 (19.3)    67 (21.9)    
  Low grade                   31 (10.1)    31 (10.1)    0.954     28 (9.2)     34 (11.1)    0.393
  High grade                  123 (40.2)   121 (39.5)             125 (40.8)   119 (38.9)   
  No ascites                  108 (35.3)   81 (26.5)    0.002     125 (40.8)   64 (20.9)    \<0.001
  Presence ascites            46 (15.0)    71 (23.2)              28 (9.2)     89 (29.1)    

Values are presented as number (%).

CA125, cancer antigen 125.

^a)^Chi-square test.

Discussion
==========

The present study found that NLR \>3.38 and advanced stage were independent predictive factors for platinum resistance. NLR is a very useful parameter in the prediction of chemo-responsiveness due to its ease of determination. This marker could be used to evaluate the systemic balance between neutrophil-dependent pro-tumor inflammation and lymphocyte-associated anti-immune response. High NLR could represent a trend towards increased pro-tumor inflammation and decreased anti-tumor immune capacity, which might affect the tumor response to chemotherapy \[[@B4],[@B8]\]. Miao et al. \[[@B9]\] recently published the role of preoperative NLR and PLR as prognostic markers for predicting the chemotherapeutic response and survival outcomes in 344 EOC patients who received platinum-based chemotherapy. Those authors found that an NLR \>3.02 was significant in the prediction of the chemotherapeutic responses. This cutoff point value was similar to the one found in our study. However, the authors also reported significant independent prognostic factors for survival outcomes from both NLR and PLR, whereas in our study, only a high PLR was found to be an independent prognostic factor for poor survival. The cutoff point of PLR in the Miao study \[[@B9]\] was 207, which was similar to the cutoff point of 210 in our study. Both PLR and NLR are promising inflammatory biomarkers of chronic inflammation, which is a key factor in all stages of cancer formation, including initiation, promotion, development and progression of ovarian cancer \[[@B10]\]. Tian et al. \[[@B11]\] recently published a meta-analysis of the prognostic significance of PLR. They performed 11 studies comprising 3,574 patients with EOC and demonstrated that a PLR above 200 revealed a negative impact to both progression-free survival and overall survival. In regards to the NLR, Huang et al. \[[@B12]\] carried out a meta-analysis by recruiting 12 studies, totaling 3,854 EOC patients. They found that a high pre-treatment NLR level was significantly associated with poorer overall survival (HR of 1.69) and shorter progression-free survival (HR of 1.63), as well as a lower chemotherapeutic response (OR, 0.53). The cutoff points of these studies were within a range of 2.11--3.91. The inconsistent outcomes between the present study and previous publications that reported that NLR was significant in platinum resistance but did not affect survival outcomes, whereas the PLR was significant only in the survival outcomes might be due to several reasons. The first is in relation to the differing cutoff points. Our cutoff level was based on the platinum status and not on the survival outcome. Second, the variation in the population may have had an impact, as our study recruited data from fallopian tube cancer and primary peritoneal adenocarcinoma patients, in addition to EOC patients. This was because of the similar treatment guidelines \[[@B13]\]. However, most previous studies recruited only EOC patients, which may have had an impact on the findings \[[@B12]\]. Finally, patients who received initial treatment with neoadjuvant chemotherapy were also enrolled in our study, which again was anomalous to methods used in other studies.

Regarding other predictive factors for chemotherapy resistance, our study found advanced stage was a significant independent factor. To explain this, Li et al. \[[@B14]\] suggested that the mechanism involved in chemotherapeutic resistance incorporates the self-renewal and differentiated properties of cancer stem cells, which could be dividing to give rising resistant cells and this mechanism was more common in cancer cells from advanced staged tumors. Due to cancer cells being more resistant to chemotherapy, patients with advanced stage cancers had very poor survival outcomes.

Our study found that high NLR and PLR were more commonly found in patients with high CA125 levels, at an advanced stage, with suboptimal residual tumors, high-grade histology and the presence of ascites. These factors were the main poor prognostic factors for the outcomes of patients with EOC \[[@B2]\].

The strength of our study was the high number of datasets from patients in one institution. This should have decreased the level of variation from blood test laboratory results. However, the very nature of a retrospective study means that some data may be missed, and the precise cause of death reported, and hence the cancer-specific survival outcomes, may not be completely accurate. Thus, greater-designed prospective studies, with adequate numbers of participants that could be controlled for the variable factors, such as neoadjuvant chemotherapy, type of surgery, and type of chemotherapy are needed.

In conclusion, high NLR and advanced stage were potential independent predictive factors for platinum resistance, whereas high PLR and advanced stage were potential independent predictive factors for poor survival outcomes in EOC, fallopian tube cancer, and primary peritoneal adenocarcinoma patients treated with platinum-based chemotherapy. A novel therapy might be beneficial for these patients.
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